Several imaging, CSF, and blood biomarker studies have demonstrated that GFAP levels are higher in patients with MCI and/or AD than in cognitively unimpaired individuals, suggesting the potential for GFAP to complement existing AD biomarkers as a possible indicator of the neuroinflammatory aspects of neurodegenerative progression [10–12]. Here, GFAP is linked to Alzheimer disease.